Studying the metabolism of sorafenib (Nexavar®) by OATP1B blockage in adult cancer patients

Completed

• Conditions: tevens nier- en schildkliercarcinomen; cancer malignancy; 10019815

• Registration Number: NL-OMON38631
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 9

Inclusion Criteria

- Adults with cancer, in which sorafenib treatment is indicated.
- Adequate organ function.

Exclusion Criteria

- Use of other CYP3A4 substrates.
- Prior liver transplant.
- Patients unable to undergo study procedures.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Plasma levels of sorafenib with and without preceding rifampicin<br /><br>administration.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Midazolam clearance test.<br /><br>- Side effects following interaction between study medication.<br /><br>- Analysis of the influence of genetic polymorphisms at baseline on sorafenib<br /><br>plasma levels.</p><br>